Atria Investments Inc Sells 756 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Atria Investments Inc decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.6% during the third quarter, HoldingsChannel reports. The fund owned 20,349 shares of the medical research company’s stock after selling 756 shares during the quarter. Atria Investments Inc’s holdings in Charles River Laboratories International were worth $4,008,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CRL. Vanguard Group Inc. grew its position in Charles River Laboratories International by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 6,046,467 shares of the medical research company’s stock valued at $1,638,290,000 after acquiring an additional 66,161 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC increased its position in shares of Charles River Laboratories International by 1.7% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company’s stock worth $394,359,000 after acquiring an additional 31,359 shares during the period. Allspring Global Investments Holdings LLC grew its position in shares of Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after buying an additional 509,163 shares in the last quarter. Clearbridge Investments LLC grew its holdings in Charles River Laboratories International by 3.1% during the 1st quarter. Clearbridge Investments LLC now owns 1,513,138 shares of the medical research company’s stock worth $409,985,000 after acquiring an additional 45,079 shares in the last quarter. Finally, Meritage Group LP increased its holdings in Charles River Laboratories International by 2.3% during the first quarter. Meritage Group LP now owns 1,182,268 shares of the medical research company’s stock valued at $320,336,000 after buying an additional 26,892 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $215.84 on Wednesday. Charles River Laboratories International, Inc. has a fifty-two week low of $168.24 and a fifty-two week high of $275.00. The company has a 50 day moving average price of $194.85 and a 200 day moving average price of $207.91. The stock has a market capitalization of $11.04 billion, a P/E ratio of 27.01, a PEG ratio of 5.80 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.21 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same period in the previous year, the firm posted $2.72 EPS. Charles River Laboratories International’s revenue for the quarter was down 1.6% on a year-over-year basis. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 10.2 EPS for the current year.

Charles River Laboratories International announced that its board has approved a stock buyback program on Wednesday, August 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 9.6% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Citigroup downgraded shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and lowered their target price for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. Baird R W downgraded shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 8th. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 target price for the company. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Finally, Barclays dropped their price objective on shares of Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $217.54.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).